Articles and resources

Prenatal
03 Aug 2021

Improved outcomes through pre-eclampsia management: Different solutions for different needs

Professor Jon Hyett, Head of High-Risk Obstetrics and a Senior Staff Specialist in Obstetrics, and Maternal and Fetal Medicine Royal Prince Alfred Hospital, Sydney, Australia
A historical perspective on Sickle Cell Disease: How did we get here?
Newborn
13 Jul 2021

A historical perspective on Sickle Cell Disease: How did we get here?

In her enlightening presentation, Dr. Venée N. Tubman takes a historical perspective on our understanding of Sickle Cell Disease. From African folk beliefs and oral histories, to early clinical observations in the 19th century, to the first newborn screening efforts in the USA in the 1970s, to the present challenges in sub-Saharan Africa. Dr. Tubman discusses how newborn screening could make a great difference in future decades, and what potentially lies ahead. See the presentation for great insights on SCD.
Consortium on Newborn Screening in Africa: news from Nigeria
Newborn
13 Jul 2021

Consortium on Newborn Screening in Africa: news from Nigeria

Nigeria is severely burdened by Sickle Cell Disease, with an estimated of 150,000 babies born with SCD each year. Many infants do not reach adolescence, however about 70% of deaths could be prevented with low-cost diagnostic and treatment plans. In her presentation, Professor Obiageli Nnodu discusses the future hopes for Nigeria, including ongoing newborn screening projects and learning ways to develop and expand screening programs.
Showing the benefits of early intervention for children with SCD
Newborn
13 Jul 2021

Showing the benefits of early intervention for children with SCD

More than 300,000 babies are born with Sickle Cell Disease (SCD) each year in sub-Saharan Africa, many resulting in death by the age of five. The Consortium on Newborn Screening in Africa (CONSA) and their network of partners are taking life-saving action by demonstrating the effectiveness of early intervention. The aim to screen up to 10,000–20,000 babies per country annually and to provide clinical follow-up for SCD-positive babies. See a presentation by Dr. Maureen Achebe to learn more.
A Case of SMA with Pompe Disease in India
Newborn
09 Jun 2021

A Case of SMA with Pompe Disease in India

In a recent case in India, a child was diagnosed with simultaneous Pompe disease and spinal muscular atrophy (SMA). See Dr. Priyanshu Mathur’s presentation to learn more about the rare case and how the child was identified for treatment.
Newborn screening for LSDs – a pilot study from Brazil
Newborn
09 Jun 2021

Newborn screening for LSDs – a pilot study from Brazil

Early diagnosis of lysosomal storage disorders is essential for better patient outcomes. In her presentation, Dr. Francyne Kubaski of the Medical Genetics Service of Brazil shares the learnings from an LSD newborn screening pilot study using tandem mass spectrometry. The study was conducted using PerkinElmer’s NeoLSD ™ MSMS kit, which enables screening of up to six lysosomal storage disorders from a single blood spot punch. See the video to learn more.
Genomic sequencing in newborns – yes or no?
Newborn
09 Jun 2021

Genomic sequencing in newborns – yes or no?

It’s technically possible to produce high-quality genomic sequencing data from blood spot cards used in newborn screening. However, there are cost considerations, ethical issues as well as limitations in infrastructure and human resources to delivering genomic sequencing at scale. What additional value would genomic sequencing bring to newborn screening? For fresh insights, see the presentation by Professor John Christodoulou of the University of Melbourne Department of Paediatrics.
Molecular testing in newborn screening: how far we’ve come
Newborn
09 Jun 2021

Molecular testing in newborn screening: how far we’ve come

In her presentation, Professor Mei Baker of the University of Wisconsin Department of Pediatrics discusses the state of molecular testing in newborn screening. Wisconsin’s screening program covers 47 disorders, including hemoglobinopathies, fatty acid disorders, amino acid disorders and the latest addition, Spinal Muscular Atrophy (SMA). Click below to learn some of the latest results and insights in molecular testing.
How do you keep your newborn screening program running under COVID-19 pressure?
Newborn
09 Jun 2021

How do you keep your newborn screening program running under COVID-19 pressure?

Under these extraordinary circumstances, it takes some creative maneuvering to keep your newborn screening program going efficiently. Professor Carmencita Padilla of the University of the Philippines shares the lessons learned from the creative strategies and continuity plans implemented throughout the Philippine newborn screening program. See her presentation for practical advice and ideas on how to run your program under COVID-19 pressure.
Performance of commercially available placental growth factor tests in women with suspected preterm pre‐eclampsia; the COMPARE study
Prenatal
09 Jun 2021

Performance of commercially available placental growth factor tests in women with suspected preterm pre‐eclampsia; the COMPARE study

F.P. McCarthy et. al. Ultrasound in Obstetrics & Gynecology

Products may not be licensed in accordance with the laws in all countries, such as the United States, Canada. Please check with your local representative for availability.

PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations please consult your local health care professionals.